NAMS

NASDAQ 已收盘

NewAmsterdam Pharma Company N.V.

27.55 USD
-0.30+0.22%
盘后 27.97 +1.75%
2026-08-03
市值
$3.22B
市盈率
EPS
-1.77
股息率
52 周区间
21.23 – 42.21
成交量
1.08M
Beta
0.08
目标价
51.43
52W 低 21.2352W 高 42.21
价格走势

公司简介

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartere...